In a landmark decision that could set a precedent on how life-saving drugs under patents can be made affordable, the government has allowed a domestic company, Natco Pharma, to manufacture a copycat version of Bayer's patented anti-cancer drug, Nexavar, bringing down its price by 97%. In the first-ever case of compulsory licencing approval, the Indian Patent Office on Monday cleared the application of Hyderabad's Natco Pharma to sell generic drug Nexavar,...

The Swiss-based pharmaceutical giant Novartis is taking the state of India to court in a case that has, after rumbling about in the lower courts for six years, wound up as a very public litmus test of the legal framework sustaining India’s generic drugs revolution.  With the case due before the Supreme Court on 28 March, the fate of millions who depend on affordable Indian medicines may soon hang in the...

The recommendations of the Planning Commission’s High Level Expert Group on Access to Universal Healthcare are significant because they make explicit the need to contextualise health within the rights. However, the problem with the report is that it does not ask why many of the same recommendations that were made by previous committees have not been implemented. The HLEG neither recognises the problems, constraints and compulsions at the national, state...

-The Times of India Free medicines to all patients visiting any government health facility across the country could soon be a reality with the health ministry ready to roll out a nearly Rs 30,000 crore 'free-medicines-for-all' scheme with the PMO's strong backing. The free medicine initiative along with an expansion of the National Rural Health Mission to urban areas, a more district-oriented approach and implementation of recommendations of the K Srinath Reddy...

-The Hindu With the Supreme Court issuing notice to the Central government on the matter of illegal drug trials, the sordid state of human clinical trials is all set to be exposed. For multinational companies eager to cut corners, India offers an attractive package of weak laws, lax and almost non-existent oversight of trials, a huge illiterate, vulnerable population that can be easily exploited, very little volunteer protection and a sizeable...